VRB-104
Undisclosed
PreclinicalActive
Key Facts
About Verdiva Bio
Verdiva Bio is a well-funded private biotech targeting the massive obesity and cardiometabolic market with a differentiated pipeline of peptide-based therapies. Its lead asset, VRB-101, is an oral, once-weekly GLP-1 analog (ecnoglutide) currently in Phase 2b development, supported by a proprietary oral absorption enhancer. The company is also developing amylin-based candidates and combinations, positioning itself in the next wave of incretin/amylin therapies with a focus on oral and convenient dosing. Backed by over $410M in Series A financing and a seasoned leadership team, Verdiva aims to become a key player in the evolving metabolic disease landscape.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |